The start-up has focused its research on the development of new drugs for the treatment of chronic inflammatory and neurodegenerative pathologies.
It is developing a new technology, upstream of existing therapies, which aims to treat the neurogenic inflammation underlying many chronic inflammatory pathologies.
The results of its research will make it possible to consider the development of drugs for first line treatments, effective and well tolerated, for peripheral neuropathy (of diabetic origin or not), cutaneous dysesthesia, scars, psoriasis and other immune or neurodegenerative diseases.
The start-up’s objective, in the short term, is to devote itself to a drug development program for diabetic peripheral neuropathic pain (DPNP) with the aim of preclinical development in 2022. Subsequently, it will develop a drug candidate for performing human clinical trials.
The most commonly used current treatments for peripheral neuropathic pain are anticonvulsants (Lyrica® product from Pfizer laboratory) and antidepressants (Cymbalta® product from Eli Lilly laboratory).
Peripheral Neuropathic Pain care expenses amounted to USD 3.61 billion in 2018, and have a CAGR of 8.9% *
*Fortune Business Insights 2020 – Healthcare – Diabetic Neuropathy Market Size, Shares and Global Report
About OLYS Pharma
OLYS Pharma is an innovative biotech whose mission is to improve the quality of life of patients suffering from neurogenic inflammation and the inconveniences it causes.
RELATED POSTS